Ehlers-Danlos syndrome musculocontractural type 2

Summary
Definition
An Ehlers-Danlos syndrome that is characterized by progressive multisystem fragility-related manifestations, including joint dislocations and deformities; skin hyperextensibility, bruisability, and fragility, with recurrent large subcutaneous hematomas; cardiac valvular, respiratory, gastrointestinal, and ophthalmologic complications; and myopathy, featuring muscle hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in histology in adulthood, resulting in gross motor developmental delay and that has_material_basis_in homozygous mutation in the DSE gene on chromosome 6q22.
Super Class
Ehlers-Danlos syndrome autosomal recessive disease
Disease Ontology
DOID:0080737
Mondo Disease Ontology
OMIM
Related Genes
Displaying 1 entry
Gene ID Gene Symbol Description Source
29940 DSE dermatan sulfate epimerase
Displaying 1 entry
Gene ID Gene Symbol Description Source
212898 Dse dermatan sulfate epimerase
The Human Phenotype Ontology
Displaying entries 51 - 60 of 85 in total
HPO ID HPO Term
HP:0003196 Short nose
HP:0003198 Myopathy
HP:0003199 Decreased muscle mass
HP:0003319 Abnormality of the cervical spine
HP:0003414 Atlantoaxial dislocation
HP:0004794 Malrotation of small bowel
HP:0005272 Prominent nasolabial fold
HP:0006184 Decreased palmar creases
HP:0007906 Ocular hypertension
HP:0012534 Dysesthesia
Displaying all 2 entries
Gene ID Gene Symbol Description
113189 CHST14 carbohydrate sulfotransferase 14
29940 DSE dermatan sulfate epimerase

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.1.0

Last updated: December 9, 2024